The impact of tardive dyskinesia can be serious

Tardive dyskinesia (TD) can be disruptive to patients and affect their lives.1 Caregivers can also feel burdened by TD, as they may be the first to notice signs of TD.2*

*Based on interviews with neurologists (n=88), psychiatrists (n=78), and primary care physicians (n=53) about the perceived burden of TD on patients and caregivers and about who first noticed TD signs.2

Burden of illness: the consequences of tardive dyskinesia

TD can be disruptive to patients, whether they have mild, moderate, or severe TD.3

Patients with TD may deal with many issues, such as

  • Abnormal and involuntary movements may cause embarassment in public1
  • Loss of physical control may make those around them feel uncomfortable1
  • Psychiatric patients may already have difficulty gaining stability and social acceptance1,4
It’s difficult to take care of somebody with those movements. You never know from one day to the next how bad it’s going to be. It could change hour to hour, so it’s really hard. Caregiver

The prevalence of tardive dyskinesia may be greater than you think

TD is estimated to affect at least 500,000 people in the United States.5,6 Up to 50% of TD patients may be uncoded.7‡

TD diagnosis challenges may include

  • Patients not knowing how to recognize TD8
  • The complex nature of TD9,10
  • Medical-legal concerns1
  • Historical lack of a specific FDA-approved treatment for TD11
Of the 5 million people in the US taking antipsychotics, ≥ 500,000 may have tardive dyskinesia (TD) and up to 50% may be uncoded.
Based on online surveys with psychiatrists (n=101) and neurologists (n=100) who were familiar with coding processes. Physicians represented solo, group, and hospital/mental health center practice settings across each specialty. Physicians were asked how often TD is not coded.7

Take on TD: How much has antipsychotic use increased?

Chart that shows a 4x increase in antipsychotic use over 23 years (~15,000,000 in 1992 to ~60,000,000 in 2014). Chart that shows a 4x increase in antipsychotic use over 23 years (~15,000,000 in 1992 to ~60,000,000 in 2014). Up to 50% of TD patients may be uncoded.7‡ Download a brochure to learn more about TD.

Take on TD and start the conversation

Foster an open dialogue with your patients and their caregivers about TD. Caregivers in particular may be more aware of the signs than their loved ones, especially in cases of severe mental illness.13§

§Based on physician interviews (N=50) about the management and impact of TD.13 TALK WITH YOUR PATIENTS AND CAREGIVERS ABOUT TD. SIGN UP FOR RESOURCES TO HELP YOU START THE CONVERSATION

APA Guideline recommendations1

  • Screen for TD before starting or restarting patients on DRBA treatment
  • Monitor for signs of TD every few months
  • Consider a diagnostic evaluation

Next: Risk for TD

It's important to know who's most susceptible to TD.

Find out who's at risk
References: 1. Task Force on Tardive Dyskinesia. Tardive Dyskinesia: A Task Force Report of the American Psychiatric Association. American Psychiatric Association; Washington, DC; 1992. 2. Data on file. Neurocrine Biosciences. 3. Othman Z, Ghazali M, Razak AA, et al. Severity of tardive dyskinesia and negative symptoms are associated with poor quality of life in schizophrenia patients. Int Med J. 2013;20(6):677-680. 4. Boumans CE, de Mooij KJ, Koch PA, et al. Is the social acceptability of psychiatric patients decreased by orofacial dyskinesia? Schizophr Bull. 1994;20(2):339-344. 5. Cloud LJ, Zutshi D, Factor SA. Tardive dyskinesia: therapeutic options for an increasingly common disorder. Neurotherapeutics. 2014;11(1):166-176. 6. Data on file. Neurocrine Biosciences. 7. Data on file. Neurocrine Biosciences. 8. Macpherson R, Collis R. Tardive dyskinesia: patients' lack of awareness of movement disorder. Br J Psychiatry. 1992;160:110-112. 9. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Arlington, VA: American Psychiatric Association; 2013:712. 10. Schooler N, Kane J. Research and diagnoses for tardive dyskinesia. Arch Gen Psychiatry. 1982;39(4):486-487. 11. US Food and Drug Administration. Center for Drug Evaluation and Research. http://www.accessdata.fda.gov/scripts/cder/drugsatfda. Accessed September 7, 2016. 12. IMS Institute for Healthcare Informatics. Report to Neurocrine Biosciences, Inc. 1992-2014. 13. Data on file. Neurocrine Biosciences.

Sign up to take on tardive dyskinesia [TD]

Thank you for your interest in receiving resources on the signs of and risks for TD.

Once you're signed up, remember to check your email for your TD resource.


If you are a patient or family member/caregiver, please click here.

I'm

We're sorry! Only US healthcare professionals may register.

Email is required, but please select other communication methods below:
*Data fees may apply.
Please indicate below that you accept

Almost finished...

Thank you for submitting your information.

Please check your email inbox to confirm your subscription. If you do not receive an email, please check your spam or junk folder, as the message may have been filtered.

You are now leaving the Take On TD website

Neurocrine is not responsible for the content of linked third-party websites. Please be aware that the privacy policies and terms of use on these sites are different from Neurocrine policies.

STAY HERE LEAVE SITE